We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-4.93%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$98.8B
AUM Growth
-$3.4B
Cap. Flow
+$2.69B
Cap. Flow %
2.72%
Top 10 Hldgs %
24.29%
Holding
4,219
New
200
Increased
1,781
Reduced
1,776
Closed
283
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EWZ icon
2326
iShares MSCI Brazil ETF
EWZ
$8.47B
$1.12M ﹤0.01%
37,747
+3,779
+11% +$112K
GOOS
2327
Canada Goose Holdings
GOOS
$851M
$1.11M ﹤0.01%
73,002
+8,468
+13% +$158K
EPRF icon
2328
Innovator S&P Investment Grade Preferred ETF
EPRF
$68.6M
$1.11M ﹤0.01%
59,465
-6,579
-10% -$131K
TRUP icon
2329
Trupanion
TRUP
$1.34B
$1.11M ﹤0.01%
18,703
+1,098
+6% +$73.7K
SAH icon
2330
Sonic Automotive
SAH
$2.54B
$1.11M ﹤0.01%
25,616
+15
+0.1% +$680
ABEQ icon
2331
Absolute Select Value ETF
ABEQ
$145M
$1.11M ﹤0.01%
+44,085
New +$1.18M
ENV
2332
DELISTED
ENVESTNET, INC.
ENV
$1.11M ﹤0.01%
24,947
-424
-2% -$22.6K
TNDM icon
2333
Tandem Diabetes Care
TNDM
$1.57B
$1.11M ﹤0.01%
23,113
+4,935
+27% +$271K
DSM
2334
BNY Mellon Strategic Municipal Bond Fund
DSM
$291M
$1.1M ﹤0.01%
194,840
-2,584
-1% -$16.4K
FDIS icon
2335
Fidelity MSCI Consumer Discretionary Index ETF
FDIS
$1.72B
$1.1M ﹤0.01%
18,123
-3,821
-17% -$256K
DDS icon
2336
Dillards
DDS
$9.07B
$1.1M ﹤0.01%
+4,041
New +$1.07M
OTTR icon
2337
Otter Tail
OTTR
$3.89B
$1.1M ﹤0.01%
17,909
+276
+2% +$19.9K
EPI icon
2338
WisdomTree India Earnings Fund ETF
EPI
$2.03B
$1.1M ﹤0.01%
36,036
-2,625
-7% -$83.4K
PDCE
2339
DELISTED
PDC Energy, Inc.
PDCE
$1.1M ﹤0.01%
19,046
-2,645
-12% -$162K
BRBR icon
2340
BellRing Brands
BRBR
$1.26B
$1.1M ﹤0.01%
53,341
+10,014
+23% +$241K
BLNK icon
2341
Blink Charging
BLNK
$84.6M
$1.09M ﹤0.01%
61,356
-304
-0.5% -$6.24K
STAA icon
2342
STAAR Surgical
STAA
$1.28B
$1.08M ﹤0.01%
15,373
+605
+4% +$51.8K
PD icon
2343
PagerDuty
PD
$919M
$1.08M ﹤0.01%
46,929
+827
+2% +$21.3K
BCLI
2344
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.08M ﹤0.01%
16,320
+3,826
+31% +$192K
UNFI icon
2345
United Natural Foods
UNFI
$2.92B
$1.08M ﹤0.01%
31,297
+12,480
+66% +$532K
ADT icon
2346
ADT
ADT
$5.47B
$1.07M ﹤0.01%
143,107
-361,529
-72% -$2.73M
DFAE icon
2347
Dimensional Emerging Core Equity Market ETF
DFAE
$9.81B
$1.07M ﹤0.01%
+53,302
New +$1.2M
UUP icon
2348
Invesco DB US Dollar Index Bullish Fund
UUP
$414M
$1.07M ﹤0.01%
35,477
+11,681
+49% +$338K
AVNT icon
2349
Avient
AVNT
$4.21B
$1.07M ﹤0.01%
35,221
+4,676
+15% +$194K
MTG icon
2350
MGIC Investment
MTG
$6.36B
$1.07M ﹤0.01%
83,143
-17,646
-18% -$247K

Similar funds

Raymond James & Associates's Q3 2022 Portfolio in Review

As of Q3 2022, Raymond James & Associates held 4,219 positions worth $98.8B, down 3.3% from $102B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q3 2022 filing shows 200 new, 1,781 increased, 1,776 reduced and 283 closed positions. Its largest new stake was JPMorgan Nasdaq Equity Premium Income ETF: 332,653 shares worth $13.9M. The largest sale was iShares Core 1-5 Year USD Bond ETF, an estimated $255M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q3 2022 buy was JPMorgan Nasdaq Equity Premium Income ETF: 332,653 shares worth $13.9M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q3 2022, an estimated $620M increase.
  • Raymond James & Associates's biggest Q3 2022 reduction was iShares Core 1-5 Year USD Bond ETF, cutting an estimated $255M.
  • Raymond James & Associates fully exited CDK Global, Inc. in Q3 2022, selling an estimated $36M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $98.8B portfolio in Q3 2022.
  • Raymond James & Associates opened 200 new positions and closed 283 in Q3 2022.
  • Raymond James & Associates's portfolio value fell 3.3% quarter-over-quarter to $98.8B.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.